Genmab A+s

Genmag A/s

Patrick Van Berkel

Paul Parren

Janine Schuurman

Jan Van De Winkel

Aran Frank Labrijn

Tom Vink

Ewald T J Van Den Bremer

Joyce Meesters

Joost J Neijssen

Willem Karel Bleeker

Frank Beurskens

Bart De Goeij

Sandra Verploegen

Steen Lisby

David Satijn

Arnout F Gerritsen

Michael J Gramer

Amitava Kundu

Wim Bleeker

Werner L Vos

Patrick Priem

Muriel Van Kampen

Marije Overdijk

Catharina Emanuele Gerarda Havenith

Riemke Van Dijkhuizen

Ewald Van Den Bremer

Kristin Strumane

Joyce I Meesters

Ewald TJ Van Den Bremer

Jan GJ Van De Winkel

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.

Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains

The present invention relates to an in vitro method for production of heterodimeric proteins.

Production of heterodimeric proteins

The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Recombinant IgG4 monovalent antibodies

Provided are antibody variants having decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to the presence or absence of C-terminal lysines of their heavy chains. Also provided are methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of such antibodies.

The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

Recombinant monovalent antibodies and methods for production thereof

The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.

Potency assays for antibody drug substance binding to an Fc receptor

Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

Human antibodies and antibody-drug conjugates against CD74

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Human antibody drug conjugates against tissue factor

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Growing community of inventors

Utrecht, Netherlands

Patrick Van Berkel